Aptar's Intranasal Technology to Be Used for Milestone's FDA-Approved Heart Treatment

Dow Jones

2025/12/18

By Elias Schisgall

Aptar Group said its intranasal medical delivery technology will be used to administer Cardamyst, a treatment for paroxysmal supraventricular tachycardia in adults.

The consumer technology company said Wednesday that its Bidose Liquid Nasal Spray System would be the mechanism to deliver Cardamyst, a drug developed by Milestone Pharmaceuticals to treat symptoms of PSVT, a condition that causes a sudden elevated heart rate.

Cardamyst received Food and Drug Administration approval last week.

Aptar Group said it collaborated with Milestone to build a custom delivery system with a fully integrated cap for Cardamyst, designed to prevent accidental activation or other user errors.

"This approval underscores the broadening of Aptar's drug delivery solutions for more therapeutic areas and the growing demand for nasal drug delivery," Aptar Pharma President Gael Touya said. "We are pleased that our trusted and proven Bidose nasal system, combined with our protective dual-container system, is now available for patients in yet another therapeutic area."

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

December 17, 2025 17:26 ET (22:26 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2592946247"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2592946247\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2592946247?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 06:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592946247","market":"sh","top_or_hot":-1,"title":"Aptar's Intranasal Technology to Be Used for Milestone's FDA-Approved Heart Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ATR\">Aptar</a> Group said its intranasal medical delivery technology will be used to administer Cardamyst, a treatment for paroxysmal supraventricular tachycardia in adults. \n</p>\n<p>\n  The consumer technology company said Wednesday that its Bidose Liquid Nasal Spray System would be the mechanism to deliver Cardamyst, a drug developed by Milestone Pharmaceuticals to treat symptoms of PSVT, a condition that causes a sudden elevated heart rate. \n</p>\n<p>\n  Cardamyst received Food and Drug Administration approval last week. \n</p>\n<p>\n  Aptar Group said it collaborated with Milestone to build a custom delivery system with a fully integrated cap for Cardamyst, designed to prevent accidental activation or other user errors. \n</p>\n<p>\n  \"This approval underscores the broadening of Aptar's drug delivery solutions for more therapeutic areas and the growing demand for nasal drug delivery,\" Aptar Pharma President Gael Touya said. \"We are pleased that our trusted and proven Bidose nasal system, combined with our protective dual-container system, is now available for patients in yet another therapeutic area.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 17, 2025 17:26 ET (22:26 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aptar's Intranasal Technology to Be Used for Milestone's FDA-Approved Heart Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptar's Intranasal Technology to Be Used for Milestone's FDA-Approved Heart Treatment\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-12-18 06:26</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ATR\">Aptar</a> Group said its intranasal medical delivery technology will be used to administer Cardamyst, a treatment for paroxysmal supraventricular tachycardia in adults. \n</p>\n<p>\n  The consumer technology company said Wednesday that its Bidose Liquid Nasal Spray System would be the mechanism to deliver Cardamyst, a drug developed by Milestone Pharmaceuticals to treat symptoms of PSVT, a condition that causes a sudden elevated heart rate. \n</p>\n<p>\n  Cardamyst received Food and Drug Administration approval last week. \n</p>\n<p>\n  Aptar Group said it collaborated with Milestone to build a custom delivery system with a fully integrated cap for Cardamyst, designed to prevent accidental activation or other user errors. \n</p>\n<p>\n  \"This approval underscores the broadening of Aptar's drug delivery solutions for more therapeutic areas and the growing demand for nasal drug delivery,\" Aptar Pharma President Gael Touya said. \"We are pleased that our trusted and proven Bidose nasal system, combined with our protective dual-container system, is now available for patients in yet another therapeutic area.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 17, 2025 17:26 ET (22:26 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4126","symbol_name":"金屬與玻璃容器","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2592946247","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592946247","pubTimestamp":1766010360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Aptar Group said its intranasal medical delivery technology will be used to administer Cardamyst, a treatment for paroxysmal supraventricular tachycardia in adults.The consumer technology company said Wednesday that its Bidose Liquid Nasal Spray System would be the mechanism to deliver Cardamyst, a drug developed by Milestone Pharmaceuticals to treat symptoms of PSVT, a condition that causes a sudden elevated heart rate.Cardamyst received Food and Drug Administration approval last week.Aptar Group said it collaborated with Milestone to build a custom delivery system with a fully integrated cap for Cardamyst, designed to prevent accidental activation or other user errors.\"This approval underscores the broadening of Aptar's drug delivery solutions for more therapeutic areas and the growing demand for nasal drug delivery,\" Aptar Pharma President Gael Touya said. \"We are pleased that our trusted and proven Bidose nasal system, combined with our protective dual-container system, is now avai","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4126":"金属与玻璃容器","ATR":"Aptar"},"translate_title":"Aptar的鼻内技术将用于Milestone获得FDA批准的心脏治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATR":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\nAptar Group said its intranasal medical delivery technology will be used to administer Cardamyst, a treatment for paroxysmal supraventricular tachycardia in adults. \n\n\n  The consumer technology company said Wednesday that its Bidose Liquid Nasal Spray System would be the mechanism to deliver Cardamyst, a drug developed by Milestone Pharmaceuticals to treat symptoms of PSVT, a condition that causes a sudden elevated heart rate. \n\n\n  Cardamyst received Food and Drug Administration approval last week. \n\n\n  Aptar Group said it collaborated with Milestone to build a custom delivery system with a fully integrated cap for Cardamyst, designed to prevent accidental activation or other user errors. \n\n\n  \"This approval underscores the broadening of Aptar's drug delivery solutions for more therapeutic areas and the growing demand for nasal drug delivery,\" Aptar Pharma President Gael Touya said. \"We are pleased that our trusted and proven Bidose nasal system, combined with our protective dual-container system, is now available for patients in yet another therapeutic area.\" \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 17, 2025 17:26 ET (22:26 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}